Financials
Financial year 2024
ZELLIK PHARMA from Asse, company number BE0881910538, closed financial year 2024 with a result of € -93,373 after tax. For that financial year ZELLIK PHARMA recorded a gross margin of € 393,644 and equity of € 442,566. Compared with financial year 2023, the result moved from € 68,565 to € -93,373. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2025.
€ 442,566
▼ 17% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -93,373
▼ still € 68,565 profit in 2023
Profit after tax over the fiscal year.
€ 12,087
▲ 130% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 428,366.
People and assets in 2024
8.9
▼ 0.5 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 454,224
▼ 8% vs 2023
€ 51,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 31,550
▼ 36% vs 2023
Of which on lease € 7,938.
Debts at end 2024
€ 39,262
▼ 39% vs 2023
€ 17,385 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 172,407
▼ 58% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 76,495
▼ 14% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 3,381,670 | € 3,434,270 | - | - | |
| Gross margin | € 513,921 | € 599,255 | € 622,656 | € 393,644 | ▼ 37% |
| Profit after taxes | € 115,718 | € 110,430 | € 68,565 | € -93,373 | ▼ € 161,938 |
| Equity | € 356,945 | € 467,374 | € 535,939 | € 442,566 | ▼ 17% |
| Total debts | € 962,709 | € 717,202 | € 580,119 | € 728,019 | ▲ 25% |
| Cash | € 25,537 | € 2,946 | € 5,258 | € 12,087 | ▲ 130% |
| Retained profit | € 342,745 | € 453,174 | € 521,739 | € 428,366 | ▼ 18% |
| Bank debt | € 50,384 | € 63,917 | € 64,562 | € 39,262 | ▼ 39% |
| Balance sheet total | € 1,319,653 | € 1,184,576 | € 1,116,059 | € 1,170,585 | ▲ 5% |
| Employees (FTE) | 6.7 | 8.6 | 9.4 | 8.9 | ▼ 0.5 |
Key figures of ZELLIK PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to ZELLIK PHARMA?
What happened at ZELLIK PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 93,373 (▼ € 161,938 vs 2023). Source: NBB ↗
- Pharma Force NV became a director. NBB
- Start of the company according to the CBE. KBO
- New establishment in Dilbeek. KBO
In short
From € 115,718 profit in 2021 to € 93,373 loss in 2024.
Paid € 110,584 in corporate taxes since 2021.
Best year ever: 2021, with € 115,718 profit.
On average € 44,200 of value added per employee in 2024.
A new publication or filing at ZELLIK PHARMA? We notify you, reason included.
Follow ZELLIK PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of peeters mathieu management comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ZELLIK PHARMABehind ZELLIK PHARMA is Pharma Force NV. The shares are held by peeters mathieu management (100%).
Directors
According to the 2024 annual accounts
since 2018
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Brusselsesteenweg 812
1731 Asse
Elzenstraat 4
1702 Dilbeek
Active since 10 June 2006
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0881.910.538
- VAT number
- BE 0881.910.538
- Registered office
- Brusselsesteenweg 812, 1731 Asse
- Names & denominations
- ZELLIK PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 June 2006
- Peppol
- Active · Active since 13 Jun 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers